The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species

Brensocatib is a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which activates several neutrophil serine proteases (NSPs), including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in the bone marrow during the early stage of neutrophil maturatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Basso, Jessica, Chen, Kuan-Ju, Zhou, Yuchen, Mark, Lilly, LaSala, Daniel, Dorfman, Arielle, Atalla, Mary, Chun, Donald, Viramontes, Veronica, Chang, Christina, Leifer, Franziska, McDonald, Patrick P., Cipolla, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394516/
https://www.ncbi.nlm.nih.gov/pubmed/37538173
http://dx.doi.org/10.3389/fphar.2023.1208780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394516/
https://www.ncbi.nlm.nih.gov/pubmed/37538173
http://dx.doi.org/10.3389/fphar.2023.1208780

Ejemplares similares